THE COLORIMETRIC MICRO-DETERMINATION OF NON-ESTERIFIED FATTY ACIDS IN PLASMA.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to W G DUNCOMBE.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Bretylium (o-bromobenzylethyldimethylammonium) is a new type of hypotensive drug. It was estimated in extracts of human urine as the methyl orange complex. From 7 to 45% of a single oral dose was found in human urine within 9 hr. The [(14)C] labelled drug was used to investigate excretion by cats. A minor proportion of a subcutaneous dose was eliminated by cats in the faeces, probably after secretion into the bile. Most of the dose was excreted unchanged in the urine. No products of metabolism were found in either human or cat urine. The drug suffered negligible change when incubated with rat liver tissue in vitro.
A study of the distribution of [(14)C]-labelled bretylium (N-o-bromobenzyl-N-ethyl-N,N-dimethylammonium) in cat tissues at various times after subcutaneous injection suggests that the specificity of its blocking action on adrenergic neurones may be related to its selective accumulation in these neurones. The rate of rise and fall of concentration in sympathetic ganglia and postganglionic sympathetic nerves showed a close similarity to the time course of the blocking adrenergic neurones as manifested by relaxation of the nictitating membranes. Concentrations found were similar to those in adrenergic nerve trunks when topical application of the drug had caused a local block of conduction. Conduction in other types of nerve could be blocked by topical application, but in general they were less sensitive, heavily myelinated nerves being the most resistant.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.